Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses.

J Gastrointest Cancer · 2024 · PMC11347457 · PMID 39007963

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although there was no statistically significant difference between the two fixed dosages, 480 mg Q4W showed a trend of slightly better efficacy.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

In the second-line cohort of the 480 mg group, there was a trend towards improved PFS and OS; however, this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.